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4antastic Voyage Through
ardiology: From 1969 to 2008
echt and Colmer (1) deserve praise for their fantastic account of
generations of cardiology encompassed in 1 still-living patient.
s I reviewed their wonderful presentation of historical text,
mages, and videos, I could not help but reminisce about the joy of
iscovering, as a medical student, the numerous interventions
ossible in cardiology practice. During my cardiology fellowship
raining, publication of Waller’s (2) account of “crackers, breakers,
tretchers, drillers, scrapers, shavers, burners, welders and melters”
n the future treatment of coronary artery disease only added to the
xcitement about the specialty.
In my old age, however, I have become equally impressed with
he power of public health measures and the impact of prevention
3,4). Aspirin, beta-blockers, statins, and the control of blood
ressure and cholesterol play a crucial role in reducing cardiovas-
ular morbidity and mortality (4). Similarly, policy-based initia-
ives (4,5) and other public health measures that reduce population
xposure to risk factors or support health-improving behaviors,
uch as smoking cessation, increased physical activity, and a diet
ich in fruits and vegetables, play important roles, although they
re by no means as glamorous as the interventions described by
echt and Colmer (1) or chronicled by Waller (2).
Several studies from the U.S., New Zealand, Scotland, En-
land, Wales, Ireland, and Finland suggest that 45% to 75% of the
ecline in coronary mortality can be attributed to risk factor
hanges, and the remaining 25% to 55% to treatments (6). In fact,
mproved risk factor levels explained 53% to 72% (and treatments
nly 23%) of the decline in coronary mortality in Finland (7). It
ould be highly instructive to learn from Hecht and Colmer how
he spectrum of risk factors and major preventive practices changed
uring this fantastic voyage. In the words of the legendary
roadcaster, Paul Harvey, providing this account may tell “the rest
f the story” (8).
George A. Mensah, MD
National Center for Chronic Disease Prevention and
ealth Promotion
enters for Disease Control and Prevention
ailstop K-40
770 Buford Highway, NE
tlanta, Georgia 30341-3717
-mail: GMensah@cdc.gov
doi:10.1016/j.jacc.2008.12.077
lease note: The findings and conclusions in this letter are those of the author and do
ot necessarily represent the official position of the Centers for Disease Control and
revention.EFERENCES
. Hecht HS, Colmer M. Fantastic voyage: a patient’s journey through
cardiology from 1969 to 2008. J Am Coll Cardiol 2008;52:1366–9.
. Waller BF. Crackers, breakers, stretchers, drillers, scrapers, shavers,
burners, welders and melters—the future treatment of atherosclerotic
coronary artery disease? A clinical-morphologic assessment. J Am Coll
Cardiol 1989;13:969–87.
. Pearson TA, Bazzarre TL, Daniels SR, et al. American Heart Associ-
ation guide for improving cardiovascular health at the community level:
a statement for public health practitioners, healthcare providers, and
health policy makers from the American Heart Association Expert
Panel on Population and Prevention Science. Circulation 2003;107:
645–51.
. Smith SC Jr., Allen J, Blair SN, et al. AHA/ACC guidelines for
secondary prevention for patients with coronary and other atheroscle-
rotic vascular disease: 2006 update. J Am Coll Cardiol 2006;47:2130–9.
. Frieden TR, Bassett MT, Thorpe LE, Farley TA. Public health in New
York City, 2002–2007: confronting epidemics of the modern era. Int J
Epidemiol 2008;37:966–77.
. Capewell S, O’Flaherty M. What explains declining coronary mortality?
Lessons and warnings. Heart 2008;94:1105–8.
. Laatikainen T, Critchley J, Vartiainen E, Salomaa V, Ketonen M,
Capewell S. Explaining the decline in coronary heart disease mortality
in Finland between 1982 and 1997. Am J Epidemiol 2005;162:764–73.
. Paul Harvey, 1918–2009. Available at: http://www.paulharvey.com/
statements.html. Accessed May 12, 2009.
eply
e are delighted to respond to Dr. Mensah’s query regarding the
hanges in risk factors and major preventive practices during the 2
enerations of the “fantastic voyage” (1). Sadly, there is a large gap
etween progress in prevention and the spectacular progress in
iagnostic testing and intervention. This prevention gap may be
ttributed to several factors:
. In primary prevention, there is a disconnect between risk
assessment by risk factor analysis (Framingham Risk Score,
Procam, European Society of Cardiology) and the actual risk
determined by events, which is much more accurately predicted
by coronary calcium scanning (2,3).
. Despite the superiority of coronary calcium scanning to identify
candidates for aggressive prevention, its widespread use for
screening has been road-blocked by demands for randomized
controlled trials showing its effect on outcomes. This criterion
has never been fulfilled by the Framingham Risk Score,
Procam, European Society of Cardiology, or, for that matter, by
nuclear stress testing, rest and stress echocardiography, cardiac
catheterization, and most interventions. Nonetheless, they are
accepted as gospel.
. This “deadly double standard” (4) and the continued reliance
on risk-factor-based prognostication will continue to deprive
high-risk patients of the possibility of early identification,
with an unconscionable and unnecessary increased morbidity
and mortality.
. Indeed, there has been an explosion of risk factor identification
(including high-sensitivity C-reactive protein), none of which
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June 9, 2009:2197–200have added to the area under the receiver-operator character-
istic curve for the standard risk factors’ ability to prognosticate.
We think that there has not been and will not be a major
breakthrough in prevention, akin to what has dramatically
occurred in diagnostic testing and intervention, until risk
factors are used not for risk assessment, but to identify treatable
causal factors after risk has more accurately been established by
the level of subclinical atherosclerosis (5).
. To those who raise cost effectiveness concerns related to
widespread screening for subclinical atherosclerosis, reduction
in the cost of calcium scanning to the level of mammography
will make it the most cost-effective modality.
. Finally, in both secondary and primary prevention, there has
been a misplaced focus on simple changes in the treated risk
factors, for example, low-density lipoprotein, rather than on
measures of subclinical atherosclerosis and disease activity and
endothelial function to evaluate the response of the disease,
rather than the risk factors, to treatment.
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o Benefit From Cardiac
esynchronization Therapy in
symptomatic Patients
e congratulate Linde et al. (1) on the meticulously carried out
EVERSE (REsynchronization reVErses Remodeling in Systolic
eft vEntricular dysfunction) trial that addressed the question of
he clinical benefit of cardiac resynchronization therapy (CRT) in
atients with New York Heart Association (NYHA) functional
lass II and I heart failure (1). Unfortunately, the composite
rimary end point as defined per the study protocol was negative.
till, the authors conclude that CRT, in combination with optimal
edical treatment ( defibrillator), reduces the risk for heart
ailure hospitalizations and improves ventricular structure and
unction in NYHA functional class II and I. In our opinion, the pater statement is not supported by the presented data, which
hows no benefit for NYHA functional class I patients (odds ratio:
.87; 95% confidence interval: 0.37 to 2.03) in their subgroup
nalysis (Fig. 4 of Linde et al. [1]).
This disagreement raises the more philosophical question:
hether these subgroup analyses make sense if the primary end
oint is negative—maybe due to a lack of statistical power? It
eems that the well-known players such as wide QRS and low left
entricular ejection fraction are positive predictors for CRT success
ut not NYHA functional class I. Another intriguing finding of
his subgroup analysis is that patients on diuretics did improve,
hereas those not on diuretics did not. However, the use of
iuretics reduced mortality and prevented hospital admissions in
his patient population, which raises the question of whether the
se of diuretics by themselves may have accounted for the
ocumented beneficial effect (clinical composite end point, hospi-
alizations) in the CRT ON group and whether this confounding
ariable was corrected for in the main analysis (2).
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eply
e thank Dr. Osswald and colleagues for their interest in our
aper (1). The REVERSE (REsynchronization reVErses Remod-
ling in Systolic left vEntricular dysfunction) study was designed as
ne population of New York Heart Association (NYHA) func-
ional class I to II heart failure (HF) patients. We agree that the
rimary end point did not reach statistical significance (2), with
6% of patients worsened in the cardiac resynchronization therapy
CRT) ON group and 21% in the CRT OFF group (p  0.10).
he clinical composite response was designed for severe HF
atients and, to our knowledge, has not previously been used in
ildly symptomatic or asymptomatic HF patients (3).
The fact that the primary end point did not reach statistical
ignificance despite substantial improvement in left ventricular
LV) dimensions accompanied by a significantly reduced time to
rst HF related hospitalization might be due to the difference in
tility of this end point or that the observation period was not long
nough to demonstrate effects in NYHA functional class I to II
atients. Dr. Osswald and colleagues are concerned about the
